☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Stada
STADA and Alvotech Introduces Uzpruvo (Biosimilar, Stelara) Across the EU
July 22, 2024
STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases
January 10, 2024
STADA and Xbrane Report P-III Study Results of Ximluci (biosimilar, ranibizumab) for the Treatment of Neovascular Age-Related Macu...
June 23, 2023
STADA and Xbrane Launch Ximluci (biosimilar, ranibizumab) for Ophthalmic Conditions in the EU
April 3, 2023
STADA and Xbrane Receives the MHRA’s Approval for Ximluci (biosimilar, ranibizumab) to Treat Retinal Diseases
January 6, 2023
STADA and Xbrane Receive EC’s Marketing Authorization of Ximluci (biosimilar, ranibizumab) for Retinal Disorders
November 11, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.